The division bench of Delhi High Court has restrained Ahmedabad-based Finecure Pharmaceuticals from manufacturing and selling drugs with names similar to Sun Pharma Laboratories' "Pantocid" till the final disposal of suit filed by the latter.A bench comprising Justice Manmeet Pritam Singh Arora and Justice V Kameswar Rao, however, allowed Finecure to dispose of its existing stock with the name "Pantopacid", used for short-term treatment of acidity, within four months since it had been carrying out sales at least since 2023 and there had been no injunction till date."For availing this liberty, Finecure will file an affidavit of its existing stock by giving all particulars of the batch number and to filing of the said affidavit, the company will be at liberty to sell its existing stock to the retailers within the time granted. However, effective as on the date of this order, no further manufacturing or packaging of its drugs under the impugned mark 'PANTOPACID' and other formative marks will be permissible," the court said while setting aside the order passed by a judge who had refused to restrain the Ahmedabad firm, as sought by Sun Pharma Laboratories, a wholly-owned subsidiary of Sun Pharmaceutical Industries.The court said that while Finecure had recorded annual sales of ₹28.64 lakh with respect to 'Pantopacid' in 2022-23, Sun Pharma had recorded annual sales of ₹514 crore for 2021-22 with respect to 'Pantocid'. On the basis of these facts, the finding of the single judge that Finecure Pharmaceuticals had grown into a formidable market player between 2010 to 2023 is not borne out from the record, the division bench said.